Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of Geron Corp
CEO
Dr. John A. Scarlett M.D.
Employees
98
Industry
Biotechnology
Sector
Healthcare
Market cap
$3B
Company details
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Revenue
CoG
Gross profit
OE
R&D
G&A
OI
OIE
PI
NI
Revenue (Rev)
$29.48M
Cost of goods (CoG)
-$473,000.00
Gross profit (GP)
$28.68M
Operating expense (OE)
-$236.98M
Research and development (R&D)
-$113.22M
General and administrative (G&A)
-$123.76M
Operating income (OI)
-$207.97M
Other income expense (OIE)
-$147,000.00
Pretax income (PI)
-$201.19M
Net income (NI)
-$201.19M
Stock vs Industry average
-
Industry average
Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.30
Margin profit
0.00%
52 week low
$1.75
52 week high
$5.09
50-day simple moving average
$4.00
200-day simple moving average
$4.31
Percent held by insiders
0.09%
Percent held by institutions
85.36%
Dividend yield
0.00%
